475 followers
Blood。ステージⅡA以上CHLへのR-ABVD療法フェーズ2(2)。CR 81%, PR 15%, 3年EFS 83%, 3年OS 98%。治療後の末血clonotypic B-cell(CD27+ALDH+)の動向で再発を予見可と。 http://t.co/05O7UgVj
Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma
Overview of attention for article published in Blood, February 2012